Becton Dickinson and Co (BDX) : Pittenger Anderson Inc scooped up 1,080 additional shares in Becton Dickinson and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 36,635 shares of Becton Dickinson and Co which is valued at $6.1 Million.Becton Dickinson and Co makes up approximately 0.71% of Pittenger Anderson Inc’s portfolio.
Other Hedge Funds, Including , Forbes J M Co Llp reduced its stake in BDX by selling 65 shares or 1.17% in the most recent quarter. The Hedge Fund company now holds 5,480 shares of BDX which is valued at $911,269. Becton Dickinson and Co makes up approx 0.26% of Forbes J M Co Llp’s portfolio.Nippon Life Global Investors Americas reduced its stake in BDX by selling 2,860 shares or 2.01% in the most recent quarter. The Hedge Fund company now holds 139,490 shares of BDX which is valued at $23.2 Million. Becton Dickinson and Co makes up approx 2.21% of Nippon Life Global Investors Americas’s portfolio.Peak Asset Management boosted its stake in BDX in the latest quarter, The investment management firm added 114 additional shares and now holds a total of 44,033 shares of Becton Dickinson and Co which is valued at $7.3 Million. Becton Dickinson and Co makes up approx 1.58% of Peak Asset Management’s portfolio.Goss Wealth Management boosted its stake in BDX in the latest quarter, The investment management firm added 1,491 additional shares and now holds a total of 19,217 shares of Becton Dickinson and Co which is valued at $3.1 Million. Becton Dickinson and Co makes up approx 2.61% of Goss Wealth Management’s portfolio.Quantbot Technologies Lp reduced its stake in BDX by selling 13,056 shares or 77.96% in the most recent quarter. The Hedge Fund company now holds 3,692 shares of BDX which is valued at $595,372. Becton Dickinson and Co makes up approx 0.09% of Quantbot Technologies Lp’s portfolio.
Becton Dickinson and Co opened for trading at $166.5 and hit $167.3 on the upside on Wednesday, eventually ending the session at $167, with a gain of 0.56% or 0.93 points. The heightened volatility saw the trading volume jump to 7,79,074 shares. Company has a market cap of $35,438 M.
On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.